Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose GW856553 in active rheumatoid arthritis: CRP dose–response
2005-002969-37Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in rheumatoid arthritis (RA) comparing GW856553 single-dose arm with Placebo arm (2 arms). Primary endpoint: Primary: CRP levels 72 hours post-dose. Started Aug 2005; status: completed.
02
Drugs
losmapimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-002969-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002969-37.